Long, uncertain time to market. Extremely high costs. High failure rate. These are still critical risk factors facing today’s pharmaceutical companies as they develop life-changing medicines.
BullFrog AI, an emerging digital biopharma company, is committed to changing that paradigm.
Using our proprietary AI/ML analytics platform, we aim to improve drug development and clinical trials through identification of high-value data niches and patient subgroups. This will ultimately lead to improved clinical outcomes for patients, and reduction of trial-and-error treatment strategies in our disease areas of focus.
Our mission is to improve lives by identifying critical connections between therapies and highly responsive patients – in less time, with less cost, and more precision.
With the bfLEAP™ platform, BullFrog AI discovers therapies that simply wouldn’t be found with other AI platforms. This innovative technology is unmatched and sets a new bar for precision medicine.
As many new medicines are developed for patients, many are still left undiscovered. The bfLEAP™ platform offers the potential to discover new mechanisms with the clinical data set, that would benefit subgroups of patients. By revitalizing these existing mechanisms, more therapies become available to help more patients live a better life.
For drug candidates in clinical trials, the bfLEAP™ platform analyzes such clinical trial data sets to predict which patients will respond to a particular therapy in development, thereby tailoring inclusion/exclusion criteria and enhancing primary study outcome success.